Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa

NCT00712166 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Cystic Fibrosis
Lung Infection
Pseudomonas Aeruginosa

Interventions

DRUG: AZLI 75 mg three times daily (TID)
DRUG: Placebo three times daily (TID)

Sponsor

Gilead Sciences